Skip to main content

Branded

  • Former Dendreon executive joins Onyx

    SOUTH SAN FRANCISCO, Calif. — Onyx Pharmaceuticals has appointed a new SVP global corporate affairs.

    John Osborn will be responsible for the public and government affairs activities of the company, as well as key stakeholder relationships, and will report to Onyx's president and CEO N. Anthony Coles.

    Prior to joining Onyx, Osborn previously served as EVP, general counsel and secretary at Dendreon.

  • Walgreens expands vaccination offerings in Florida

    DEERFIELD, Ill. — Walgreens on Monday announced the expansion of its vaccination offerings in Florida to include shingles and pneumonia.

  • Lilly gains U.S. pediatric exclusivity for Cymbalta

    INDIANAPOLIS — Eli Lilly announced that it has met Food and Drug Administration requirements for pediatric exclusivity for its antidepressant medication.

    Based on this decision by the FDA, Lilly has gained an additional six months of U.S. market exclusivity for Cymbalta (duloxetine hydrochloride), which now will expire in December 2013.

  • FDA accepts NDA for Agile's contraceptive patch

    PRINCETON, N.J. — The Food and Drug Administration has accepted a new drug application for a low-dose, once-weekly contraceptive patch from Agile Therapeutics, the drug maker said.

  • Amgen completes Kai acquisition

    THOUSAND OAKS, Calif. — Amgen has completed its acquisition of Kai Pharmaceuticals, a privately held company based in South San Francisco, Calif.

    The deal, first announced in April, is valued at $315 million. The deal also includes the acquisition of KAI-4169, an experimental drug Kai is developing for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI previously reported compelling mid-stage clinical results for KAI-4169 in this indication.

  • FDA orders unapproved oxycodone drugs off market

    SILVER SPRING, Md. — The Food and Drug Administration is asking companies to stop manufacturing and distributing unapproved drugs containing the painkiller oxycodone, the agency said Thursday.

  • Bristol-Myers Squibb buys Amylin for $5.3 billion

    NEW YORK — Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

    Bristol announced that it would acquire Amylin for $5.3 billion, or $31 per share. The total value of the acquisition is about $7 billion, including $1.7 billion in Amylin's contractual payment and debt obligations.

  • FDA accepts application for Shionogi VVA treatment

    FLORHAM PARK, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug made by Shionogi for treating vulvar and vaginal atrophy due to menopause.

    Shionogi, the U.S. division of Japanese drug maker Shionogi & Co., said Wednesday that the FDA had accepted for review its application for ospemifene, which the company touts as potentially the first oral alternative to vaginal estrogen treatments.

X
This ad will auto-close in 10 seconds